[Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].

This study purposed to investigate the correlation of expression level of e2a-pbx1 (immunoglobulin enhancer binding factor-Pre-B leukemia) with clinical characteristics and early response to treatment in children patients with acute lymphoblastic leukemia (ALL). The expression level of e2a-pbx1 at primary diagnosis in 45 children with ALL, and on day 33 after induction of remission in 23 children with ALL were detected by real-time quantitative polymerase chain reaction (RQ-PCR). The corelation of e2a-pbx1 expression level at primary diagnosis, MRD level with clinical characteristics and early response to treatment were all observed and explored. The expression level of e2a-pbx1 and clinical characteristics at primary diagnosis were compared between MRD negative and MRD positive patients. The results showed that the expression level of e2a-pbx1 was correlated with the blast percentage in peripheral blood at primary diagnosis. The MRD level at day 33 after induction of remission in 23 children were not related to the expression level of e2a-pbx1 at primary diagnosis and the clinical characteristics. The expression level of e2a-pbx1 at primary diagnosis in MRD positive patients was higher than that in MRD negative patients, while their age was significantly lower than that of patients with MRD negative. The blast percentage in peripheral blood at diagnosis of patients with presenting leukocyte count < 25 x 10(9)/L was significantly lower than that of patients with presenting leukocyte count >or= 25 x 10(9)/L, while the platelet count was higher. It is concluded that the expression level of e2a-pbx1 at primary diagnosis indicates the load of tumor in patients. In patients whose MRD were positive, the expression level of e2a-pbx1 at primary diagnosis is high and their age is young. The platelet count is low in the patients with high load of tumor at primary diagnosis.